Digestive System Neoplasm

This study examined outcomes of 240 rectum cancer patients treated with total mesorectal excision therapy. Tumor samples were obtained at the time of surgery and genotyped for PIK3CA mutations in exon… (full text at CIViC)

PMID 19903786 · He et al., 2009 · Open in CIViC

A cohort of 32 colorectal cancer patients with acquired resistance to cetuximab (PFS > 12 weeks) was analyzed for resistance mutations using targeted deep sequencing of ctDNA. One patient had the PIK3… (full text at CIViC)

PMID 28424201 · Xu et al., 2017 · Open in CIViC

In a retrospective study of 168 chemotherapy-refractory metastatic colorectal cancer patients, patients with a PIK3CA mutation (n=26) treated with cetuximab in combination with standard chemotherapy, … (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored PIK3CA G1049R (exon 20), was wildtype for KRAS, B… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

In a retrospective study of 168 chemotherapy-refractory metastatic colorectal cancer patients, patients with a PIK3CA mutation (n=26) treated with cetuximab in combination with standard chemotherapy, … (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

In a study of 413 patients with colorectal cancer who were taking aspirin since diagnosis, the frequency of PIK3CA mutations was 17% (70/413). In 530 patients with colorectal cancer not using aspirin,… (full text at CIViC)

PMID 23094721 · Liao et al., 2012 · Open in CIViC

Phosphatidylinositol 3-kinase (PIK3CA) is composed of an 85kDa regulatory subunit and a 110kDa (p110alpha) catalytic subunit. The protein encoded by this gene represents the catalytic subunit, which u… (full text at CIViC)

PMID 9742087 · Klippel et al., 1998 · Open in CIViC

The PCR-RFLP method had a capability to detect as litter as 0.4 % of mutation, and revealed 16.3 % of the PIK3CA H1047R mutation in 86 CRC tissues.A positive association between the PIK3CA H1047R muta… (full text at CIViC)

PMID 27405731 · Li et al., 2016 · Open in CIViC

In a study of 413 patients with colorectal cancer who were taking aspirin since diagnosis, the frequency of PIK3CA mutations was 17% (70/413). In 530 patients with colorectal cancer not using aspirin,… (full text at CIViC)

PMID 23094721 · Liao et al., 2012 · Open in CIViC

A cohort of 32 colorectal cancer patients with acquired resistance to cetuximab (PFS > 12 weeks) was analyzed for resistance mutations using targeted deep sequencing of ctDNA. Three patients had the P… (full text at CIViC)

PMID 28424201 · Xu et al., 2017 · Open in CIViC

A cohort of 32 colorectal cancer patients with acquired resistance to cetuximab (PFS > 12 weeks) was analyzed for resistance mutations using targeted deep sequencing of ctDNA. One patient had the PIK3… (full text at CIViC)

PMID 28424201 · Xu et al., 2017 · Open in CIViC

A cohort of 32 colorectal cancer patients with acquired resistance to cetuximab (PFS > 12 weeks) was analyzed. One patient was found to have the PIK3CA p.L938* mutation in FFPE tumour tissue prior to … (full text at CIViC)

PMID 28424201 · Xu et al., 2017 · Open in CIViC

This retrospective study examines outcomes of 158 primary sporadic colorectal cancer patients who had undergone surgical resection and were treated with 5-fluorouracil based chemotherapy. PIK3CA mutat… (full text at CIViC)

PMID 17590872 · Kato et al., 2007 · Open in CIViC

This was a retrospective clinical study of 168 metastatic colorectal cancer patients who received first line chemotherapy (made up of 5-fluorouracil (5-FU) only, 5-FU + oxaliplatin, 5-FU + irinotecan,… (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

In a randomized, double blind, placebo controlled adjuvant trial in colorectal carcinoma with PI3K pathway mutations (ALASCCA, NCT02647099; group B n = 312), aspirin 160 mg daily (group B n = 156) for… (full text at CIViC)

PMID 40961426 · Martling et al., 2025 · Open in CIViC

Three patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored PIK3CA N345K, were wildtype for KRAS, BRAF and … (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

In a retrospective study of 168 chemotherapy-refractory metastatic colorectal cancer patients, patients with a PIK3CA mutation (n=26) treated with cetuximab in combination with standard chemotherapy, … (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored PIK3CA Q546K (exon 10), was wildtype for KRAS, BR… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

In a retrospective study of 168 chemotherapy-refractory metastatic colorectal cancer patients, patients with a PIK3CA mutation (n=26) treated with cetuximab in combination with standard chemotherapy, … (full text at CIViC)

PMID 19603024 · Souglakos et al., 2009 · Open in CIViC

One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored PIK3CA R88Q, was wildtype for KRAS, BRAF and NRAS… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored PIK3CA R93W, was wildtype for KRAS, BRAF and NRAS… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored PIK3CA S158L, was wildtype for KRAS, BRAF and NRA… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

A cohort of 32 colorectal cancer patients with acquired resistance to cetuximab (PFS > 12 weeks) was analyzed for resistance mutations using targeted deep sequencing of ctDNA. One patient had the PIK3… (full text at CIViC)

PMID 28424201 · Xu et al., 2017 · Open in CIViC

Among 32 colorectal cancer patients with acquired resistance (PFS > 12 weeks) to cetuximab, one was determined to have V955I mutation. V995I allelic fractions low at start of treatment but increased i… (full text at CIViC)

PMID 28424201 · Xu et al., 2017 · Open in CIViC

This was a retrospective study of 964 colorectal cancer patients who participated in the Nurses' Health Study and the Health Professionals Follow-up Study. Of 964 patients, 803 patients had wildtype P… (full text at CIViC)

PMID 23094721 · Liao et al., 2012 · Open in CIViC

This was a retrospective study of 964 colorectal cancer patients who participated in the Nurses' Health Study and the Health Professionals Follow-up Study. Of 964 patients, 803 patients had wildtype P… (full text at CIViC)

PMID 23094721 · Liao et al., 2012 · Open in CIViC

siRNA-mediated POLA1 protein depletion sensitized DLD-1 colorectal cancer cells to the ATR inhibitors ceralasertib (AZD6738) and berzosertib (VE-822), with approximately 9-fold and 4-fold shifts in IC… (full text at CIViC)

PMID 39128273 · Schneider et al., 2024 · Open in CIViC